Nicholas Hoffman & Company LLC. lowered its stake in shares of McKesson Co. (NYSE:MCK) by 5.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,008 shares of the company’s stock after selling 227 shares during the period. Nicholas Hoffman & Company LLC.’s holdings in McKesson were worth $542,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Whittier Trust Co. lifted its holdings in McKesson by 1.6% during the first quarter. Whittier Trust Co. now owns 18,217 shares of the company’s stock worth $2,464,000 after buying an additional 291 shares during the period. Chicago Equity Partners LLC lifted its holdings in McKesson by 12.3% during the fourth quarter. Chicago Equity Partners LLC now owns 5,665 shares of the company’s stock worth $784,000 after buying an additional 620 shares during the period. Strs Ohio lifted its holdings in McKesson by 1.3% during the fourth quarter. Strs Ohio now owns 215,511 shares of the company’s stock worth $29,809,000 after buying an additional 2,699 shares during the period. Andra AP fonden lifted its holdings in shares of McKesson by 4.0% during the 4th quarter. Andra AP fonden now owns 56,800 shares of the company’s stock valued at $7,857,000 after purchasing an additional 2,200 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of McKesson by 21.4% during the 4th quarter. AQR Capital Management LLC now owns 2,766,586 shares of the company’s stock valued at $379,797,000 after purchasing an additional 487,887 shares during the last quarter. Institutional investors own 84.96% of the company’s stock.
McKesson stock traded up $3.60 during trading on Friday, hitting $149.42. The company had a trading volume of 902,930 shares, compared to its average volume of 1,730,228. The company’s 50 day simple moving average is $136.14 and its 200-day simple moving average is $142.81. The stock has a market cap of $25.80 billion, a price-to-earnings ratio of 29.13, a price-to-earnings-growth ratio of 1.60 and a beta of 0.82. The company has a current ratio of 0.99, a quick ratio of 0.56 and a debt-to-equity ratio of 1.51. McKesson Co. has a 1-year low of $112.60 and a 1-year high of $172.18.
McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, May 20th. The company reported $4.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.10 by $0.17. The business had revenue of $58.54 billion during the quarter, compared to the consensus estimate of $55.60 billion. McKesson had a net margin of 0.39% and a return on equity of 41.07%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.69 earnings per share. As a group, analysts forecast that McKesson Co. will post 15.01 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be paid a $0.41 dividend. The ex-dividend date is Friday, May 29th. This represents a $1.64 annualized dividend and a dividend yield of 1.10%. McKesson’s dividend payout ratio (DPR) is 10.97%.
MCK has been the subject of several analyst reports. Robert W. Baird upgraded McKesson from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $164.00 to $197.00 in a report on Friday, February 7th. UBS Group upgraded McKesson from a “neutral” rating to a “buy” rating and increased their price objective for the company from $151.00 to $160.00 in a report on Friday, May 15th. JPMorgan Chase & Co. increased their price objective on McKesson from $186.00 to $187.00 and gave the company an “overweight” rating in a report on Wednesday, March 18th. Cowen increased their price objective on McKesson from $174.00 to $186.00 and gave the company an “outperform” rating in a report on Thursday. Finally, ValuEngine lowered McKesson from a “sell” rating to a “strong sell” rating in a report on Friday, May 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $168.50.
In other McKesson news, CEO Brian S. Tyler sold 4,063 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $135.00, for a total value of $548,505.00. Following the completion of the transaction, the chief executive officer now owns 16,255 shares in the company, valued at $2,194,425. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 8,187 shares of company stock valued at $1,064,057. Insiders own 0.88% of the company’s stock.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Article: What is Elliott Wave theory?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.